enzh-TWfrdeitjaptrues

Latest Bing Center News

Newsweek Names Dana-Farber #3 in the World for Cancer

Newsweek Names Dana-Farber #3 in the World for Cancer

Dana-Farber has been named one of the world’s best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings. Dana-Farber was ranked #3 globally. We are the only hospital in New England to be ranked in the top 15 for oncology.

Read more..

FDA Approves Zanubrutinib for the Treatment of Waldenströms Macroglobulinemia

FDA Approves Zanubrutinib for the Treatment of Waldenströms Macroglobulinemia

“The ASPEN trial provided compelling evidence that Brukinsa is a highly active BTK inhibitor in Waldenström’s macroglobulinemia, and compared to the first-generation BTK inhibitor, showed improved tolerability across a number of clinically important side effects. The approval of BRUKINSA provides an important new option for targeted therapy in Waldenström’s macroglobulinemia,” Steven Treon, MD, PhD, director of the Bing Center for Waldenström’s Macroglobulinemia Research at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, said in a statement.

Read more..

LLS National Blood Cancer Conference, September 18, 2021

LLS National Blood Cancer Conference, September 18, 2021

This Blood Cancer Conference is one of many programs developed by The Leukemia & Lymphoma Society to meet the needs of patients, survivors, families and oncology professionals, the people who deal with blood cancer every day and the people who care for them. BCC attendees receive the most current information and access to local resources to help navigate and make informed decisions about their treatment and survivorship.

Read more..

18th International Myeloma Workshop, September 8-11, 2021

18th International Myeloma Workshop, September 8-11, 2021

The International Myeloma Workshop is the defining annual meeting in myeloma with a focus on both the basic, preclinical and the clinical aspects, including: Scientific Programs, Oral Presentations (on Basic Biology, Preclinical Trials and Clinical Studies), Consensus Panels, Poster Presentations.

Read more..

NCCN Guidelines Add Zanubrutinib as Preferred Therapy for Waldenström Macroglobulinemia

NCCN Guidelines Add Zanubrutinib as Preferred Therapy for Waldenström Macroglobulinemia

The NCCN Guidelines Version 1.2022 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL) were updated to include zanubrutinib as a preferred regimen for the primary therapy of WM/LPL along with bendamustine/rituximab, bortezomib/dexamethasone/rituximab, ibrutinib ± rituximab, and rituximab/cyclophosphamide/dexamethasone. Preferred interventions are based on superior efficacy, safety, and evidence.

Read more..

The 300 Project forges ahead with Bliss gift

The 300 Project forges ahead with Bliss gift

“We are looking at how cancer cells from patients who may not seem connected clinically may be utilizing the same networks through different mechanisms,” explains Zachary Hunter, PhD, one of the project’s leaders.

Read more..

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

This article reviews the pharmacology, clinical efficacy, safety, dosing, drug-drug interactions, and implications for advanced practitioners of BTK inhibitors in the treatment of B-cell malignancies.

Read more..

How Are BTK Inhibitors Changing Waldenstrom Patients' Outcomes?

How Are BTK Inhibitors Changing Waldenstrom Patients' Outcomes?

What are BTK Inhibitors and how are they used in treating Waldenstrom macroglobulinemia (WM)? Patient Power co-founder Andrew Schorr discusses BTK inhibitors with Dr. Steven Treon, Director from the Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute as well as the efficacy of Covalent BTK Inhibitors: ibrutinib (Imbruvica), acalabrutinib (Calquence), zanubrutinib (Brukinsa), and tirabrutinib (Velexbru). Dr. Treon reveals when a non-covalent BTK inhibitor may be a treatment option. Dr. Treon recently presented at the 2020 IWMF.

Read more..

Fighting Infection in Patients with Waldenstrom Macroglobulinemia

Fighting Infection in Patients with Waldenstrom Macroglobulinemia

The recording of this June 2 webinar is now available: Fighting Infection in Patients with Waldenstrom Macroglobulinemia, presented by Andrew Branagan, MD, PhD, Massachusetts General Hospital Cancer Center.

Read more..

LLS Virtual Blood Cancer Conference 2021

LLS Virtual Blood Cancer Conference 2021

SAVE THE DATE - Saturday, September 18, 2021. 11:30AM - 3:30PM (ET). This virtual Blood Cancer Conference (BCC) is one of many programs developed by The Leukemia & Lymphoma Society (LLS) to meet the needs of patients, survivors, families and oncology professionals, the people who deal with blood cancer every day and the people who care for them.

Read more..